Xplus Inc. Logo

Xplus Inc.

IT consultancy guiding digital transformation via enterprise architecture & program management.

373200 | KO

Overview

Corporate Details

ISIN(s):
KR7373200005
LEI:
Country:
South Korea
Address:
서울특별시 송파구 송파대로 201 A동 13층, 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

XPLUS is a business and IT consultancy that assists companies in navigating digital transformation and future-proofing their operations. The firm's consultants specialize in enterprise architecture, IT architecture, and program management, helping clients realize their strategic goals by designing and building future-ready organizational structures. XPLUS leverages expertise in modern technologies such as business platforms, digital channels, and federated cloud solutions. The company's mission is to help businesses innovate, improve customer satisfaction, and reduce costs, enabling them to become market leaders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-25 00:00
Capital/Financing Update
전환가액의조정 (제5회차)
Korean 11.0 KB
2025-08-19 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 11.7 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.3 MB
2025-08-14 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.4 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-04 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 50.1 KB
2025-07-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 56.4 KB
2025-07-18 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 25.4 KB
2025-07-18 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 15.2 KB
2025-07-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.8 KB
2025-07-14 00:00
Share Issue/Capital Change
주요사항보고서(전환사채매수선택권행사자지정)
Korean 45.3 KB
2025-07-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 30.9 KB
2025-07-10 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 50.6 KB
2025-07-10 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 8.0 KB
2025-07-09 00:00
Capital/Financing Update
[기재정정]기타경영사항(자율공시) (제3회차 BW 취득후 재매각)
Korean 17.3 KB

Automate Your Workflow. Get a real-time feed of all Xplus Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Xplus Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Xplus Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060

Talk to a Data Expert

Have a question? We'll get back to you promptly.